A review of clinical guidelines, laboratory recommendations and external quality assurance programs for monoclonal gammopathy testing

References

• Schroeder HW, Jr, Cavacini L. Structure and function of immunoglobulins. J Allergy Clin Immunol. 2010;125(2 Suppl 2):S41–S52. doi:10.1016/j.jaci.2009.09.046.
   PubMed Web of Science ®Google Scholar
• Rasmussen T, Lodahl M, Hancke S, et al. In multiple myeloma clonotypic CD38-/CD19+/CD27+ memory B cells recirculate through bone marrow, peripheral blood and lymph nodes. Leuk Lymphoma. 2004;45(7):1413–1417. doi:10.1080/10428190410001655157.
   PubMed Web of Science ®Google Scholar
• Kumar SK, Rajkumar V, Kyle RA, et al. Multiple myeloma. Nat Rev Dis Primers. 2017;3(1):17046. doi:10.1038/nrdp.2017.46.
   PubMed Web of Science ®Google Scholar
• Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–249. doi:10.3322/caac.21660.
   PubMed Web of Science ®Google Scholar
• Multiple Myeloma in Asia. International Myeloma Foundation. Myeloma.org. Published 2018. Accessed August 14, 2023.
   Google Scholar
• Kazandjian D. Multiple myeloma epidemiology and survival: a unique malignancy. Semin Oncol. 2016;43(6):676–681. doi:10.1053/j.seminoncol.2016.11.004.
   PubMed Web of Science ®Google Scholar
• Schinasi LH, Brown EE, Camp NJ, et al. Multiple myeloma and family history of lymphohaematopoietic cancers: results from the international multiple myeloma consortium. Br J Haematol. 2016;175(1):87–101. doi:10.1111/bjh.14199.
   PubMed Web of Science ®Google Scholar
• Weiss BM, Abadie J, Verma P, et al. A monoclonal gammopathy precedes multiple myeloma in most patients. Blood. 2009;113(22):5418–5422. doi:10.1182/blood-2008-12-195008.
   PubMed Web of Science ®Google Scholar
• Cardona-Benavides IJ, de Ramón C, Gutiérrez NC. Genetic abnormalities in multiple myeloma: prognostic and therapeutic implications. Cells. 2021;10(2):336. doi:10.3390/cells10020336.
   PubMed Web of Science ®Google Scholar
• Chesi M, Bergsagel PL. Advances in the pathogenesis and diagnosis of multiple myeloma. Int J Lab Hematol. 2015;37 Suppl 1:108–114. doi:10.1111/ijlh.12360.
   PubMed Web of Science ®Google Scholar
• Wang Y, Wu Y, Xu Z, et al. Cytogenetic abnormalities in patients with newly diagnosed multiple myeloma as a secondary primary malignancy: a retrospective study. Hematology. 2020;25(1):176–180. doi:10.1080/16078454.2020.1757330.
   PubMed Web of Science ®Google Scholar
• Fonseca R, Debes-Marun CS, Picken EB, et al. The recurrent IgH translocations are highly associated with nonhyperdiploid variant multiple myeloma. Blood. 2003;102(7):2562–2567. doi:10.1182/blood-2003-02-0493.
   PubMed Web of Science ®Google Scholar
• Fairfield H, Falank C, Avery L, et al. Multiple myeloma in the marrow: pathogenesis and treatments. Ann N Y Acad Sci. 2016;1364(1):32–51. doi:10.1111/nyas.13038.
   PubMedGoogle Scholar
• Girard L-P, Soekojo CY, Ooi M, et al. Immunoglobulin M paraproteinaemias. Cancers (Basel). 2020;12(6):1688–1625. doi:10.3390/cancers12061688.
   PubMed Web of Science ®Google Scholar
• Yang Z, Harrison K, Park YA, et al. Performance of the sebia CAPILLARYS 2 for detection and immunotyping of serum monoclonal paraproteins. Am J Clin Pathol. 2007;128(2):293–299. doi:10.1309/1L3CG8GK6F8VYNYH.
   PubMed Web of Science ®Google Scholar
• Jacobs JFM, Turner KA, Graziani MS, et al. An international multi-center serum protein electrophoresis accuracy and M-protein isotyping study. Part II: limit of detection and follow-up of patients with small M-proteins. Clin Chem Lab Med. 2020;58(4):547–559. doi:10.1515/cclm-2019-1105.
   PubMed Web of Science ®Google Scholar
• McCudden CR, Jacobs JFM, Keren D, et al. Recognition and management of common, rare, and novel serum protein electrophoresis and immunofixation interferences. Clin Biochem. 2018;51:72–79. doi:10.1016/j.clinbiochem.2017.08.013.
   PubMed Web of Science ®Google Scholar
• Moss MA. Moving towards harmonized reporting of serum and urine protein electrophoresis. Clin Chem Lab Med. 2016;54(6):973–979.
   PubMed Web of Science ®Google Scholar
• Tate J, Caldwell G, Daly J, et al. Recommendations for standardized reporting of protein electrophoresis in Australia and New Zealand. Ann Clin Biochem. 2012;49(Pt 3):242–256. doi:10.1258/acb.2011.011158.
   PubMedGoogle Scholar
• The International Myeloma Working Group, Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group. Br J Haematol. 2003;121(5):749–757.
   PubMed Web of Science ®Google Scholar
• Roden AC, Lockington KS, Tostrud LJ, et al. Urine protein electrophoresis and immunoelectrophoresis using unconcentrated or minimally concentrated urine samples. Am J Clin Pathol. 2008;130(1):141–145. doi:10.1309/6K33KTFA7A5VUQ1T.
   PubMed Web of Science ®Google Scholar
• Basnayake K, Stringer SJ, Hutchison CA, et al. The biology of immunoglobulin free light chains and kidney injury. Kidney Int. 2011;79(12):1289–1301. doi:10.1038/ki.2011.94.
   PubMed Web of Science ®Google Scholar
• Morrison T, Booth RA, Hauff K, et al. Laboratory assessment of multiple myeloma. Adv Clin Chem. 2019;89:1–58.
   PubMed Web of Science ®Google Scholar
• White-Al Habeeb NMA, Earle T, Spencer M, et al. Evaluation of the N-latex serum free light chain assay on the siemens BNII analyzer and agreement with the binding site FreeLite assay on the SPAPlus. Clin Biochem. 2018;51:90–96. doi:10.1016/j.clinbiochem.2017.05.009.
   PubMed Web of Science ®Google Scholar
• Jacobs JFM, de Kat Angelino CM, Brouwers HMLM, et al. Evaluation of a new free light chain ELISA assay: bringing coherence with electrophoretic methods. Clin Chem Lab Med. 2018;56(2):312–322. doi:10.1515/cclm-2017-0339.
   PubMed Web of Science ®Google Scholar
• Katzmann JA, Clark RJ, Abraham RS, et al. Serum reference intervals and diagnostic ranges for free kappa and free lambda immunoglobulin light chains: relative sensitivity for detection of monoclonal light chains. Clin Chem. 2002;48(9):1437–1444. doi:10.1093/clinchem/48.9.1437.
   PubMed Web of Science ®Google Scholar
• Hutchison CA, Plant T, Drayson M, et al. Serum free light chain measurement aids the diagnosis of myeloma in patients with severe renal failure. BMC Nephrol. 2008;9(1):11. doi:10.1186/1471-2369-9-11.
   PubMedGoogle Scholar
• Molina-Andújar A, Robles P, Cibeira MT, et al. The renal range of the κ/λ sFLC ratio: best strategy to evaluate multiple myeloma in patients with chronic kidney disease. BMC Nephrol. 2020;21(1):111. doi:10.1186/s12882-020-01771-3.
   PubMed Web of Science ®Google Scholar
• Long TE, Indridason OS, Palsson R, et al. Defining new reference intervals for serum free light chains in individuals with chronic kidney disease: results of the iStopMM study. Blood Cancer J. 2022;12(9):133. doi:10.1038/s41408-022-00732-3.
   PubMed Web of Science ®Google Scholar
• Bhole MV, Sadler R, Ramasamy K. Serum-free light-chain assay: clinical utility and limitations. Ann Clin Biochem. 2014;51(Pt 5):528–542. doi:10.1177/0004563213518758.
   PubMed Web of Science ®Google Scholar
• Tate J, Bazeley S, Sykes S, et al. Quantitative serum free light chain assay–analytical issues. Clin Biochem Rev. 2009;30(3):131–140.
   PubMedGoogle Scholar
• Te Velthuis H, Drayson M, Campbell JP. Measurement of free light chains with assays based on monoclonal antibodies. Clin Chem Lab Med. 2016;54(6):1005–1014.
   PubMed Web of Science ®Google Scholar
• Morales-García LJ, Pacheco-Delgado MS. Serum free light chain reference intervals in an optilite and their influence on clinical guidelines. Clin Biochem. 2021;92:54–60. doi:10.1016/j.clinbiochem.2021.02.008.
   PubMed Web of Science ®Google Scholar
• Visram A, Vaxman I, S Al Saleh A, et al. Disease monitoring with quantitative serum IgA levels provides a more reliable response assessment in multiple myeloma patients. Leukemia. 2021;35(5):1428–1437. doi:10.1038/s41375-021-01180-x.
   PubMed Web of Science ®Google Scholar
• Gertz MA. Waldenström macroglobulinemia: 2019 update on diagnosis, risk stratification, and management. Am J Hematol. 2019;94(2):266–276. doi:10.1002/ajh.25292.
   PubMed Web of Science ®Google Scholar
• Heaney JLJ, Campbell JP, Iqbal G, et al. Characterisation of immunoparesis in newly diagnosed myeloma and its impact on progression-free and overall survival in both old and recent myeloma trials. Leukemia. 2018;32(8):1727–1738. doi:10.1038/s41375-018-0163-4.
   PubMed Web of Science ®Google Scholar
• Paolini L, Di Noto G, Maffina F, et al. Comparison of hevylite™ IgA and IgG assay with conventional techniques for the diagnosis and follow-up of plasma cell dyscrasia. Ann Clin Biochem. 2015;52(Pt 3):337–345. doi:10.1177/0004563214564225.
   PubMed Web of Science ®Google Scholar
• Protein Marker Evaluation of Monoclonal Gammopathies. AACC.org. https://www.aacc.org/cln/articles/2015/june/protein-marker-evaluation-of-monoclonal-gammopathies.
   Google Scholar
• Palumbo A, Avet-Loiseau H, Oliva S, et al. Revised international staging system for multiple myeloma: a report from international myeloma working group. J Clin Oncol. 2015;33(26):2863–2869. doi:10.1200/JCO.2015.61.2267.
   PubMed Web of Science ®Google Scholar
• Rossi D, Fangazio M, De Paoli L, et al. Beta-2-microglobulin is an independent predictor of progression in asymptomatic multiple myeloma. Cancer. 2010;116(9):2188–2200. doi:10.1002/cncr.24959.
   PubMed Web of Science ®Google Scholar
• Koshiaris C. Methods for reducing delays in the diagnosis of multiple myeloma. Int J Hematol Oncol. 2019; 8(1):IJH13. doi:10.2217/ijh-2018-0014.
   PubMedGoogle Scholar
• Rögnvaldsson S, Love TJ, Thorsteinsdottir S, et al. Correction: Iceland screens, treats, or prevents multiple myeloma (iStopMM): a population-based screening study for monoclonal gammopathy of undetermined significance and randomized controlled trial of follow-up strategies. Blood Cancer J. 2023;13(1):39. doi:10.1038/s41408-023-00814-w.
   Google Scholar
• Oliveros Conejero R, Pascual Usandizaga P, Chércoles G. A. Optimization of workflow and screening panels for the detection of malignant monoclonal gammopathies. Adv Lab Med. 2020;1(3):20200042. doi:10.1515/almed-2020-0042.
   PubMedGoogle Scholar
• Cho J, Lee DH, Yoo G, et al. Comparison of serum and urine free light chain analysis in clinical diagnosis. Blood Res. 2022;57(4):284–289. doi:10.5045/br.2022.2022187.
   PubMed Web of Science ®Google Scholar
• Willrich MA, Katzmann JA. Laboratory testing requirements for diagnosis and follow-up of multiple myeloma and related plasma cell dyscrasias. Clin Chem Lab Med. 2016;54(6):907–919.
   PubMed Web of Science ®Google Scholar
• Dispenzieri A, Kyle R, Merlini G, et al. International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders. Leukemia. 2009;23(2):215–224. doi:10.1038/leu.2008.307.
   PubMed Web of Science ®Google Scholar
• Rajkumar SV. Multiple myeloma: 2022 update on diagnosis, risk stratification, and management. Am J Hematol. 2022;97(8):1086–1107. doi:10.1002/ajh.26590.
   PubMed Web of Science ®Google Scholar
• Rajkumar SV, Dimopoulos MA, Palumbo A, et al. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol. 2014;15(12):e538-548. doi:10.1016/S1470-2045(14)70442-5.
   Web of Science ®Google Scholar
• Go RS, Rajkumar SV. How I manage monoclonal gammopathy of undetermined significance. Blood. 2018;131(2):163–173. doi:10.1182/blood-2017-09-807560.
   PubMed Web of Science ®Google Scholar
• Kyle RA, Rajkumar SV. Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma [published correction appears in leukemia. 2014 Apr;28(4):980]. Leukemia. 2009;23(1):3–9. doi:10.1038/leu.2008.291.
   PubMed Web of Science ®Google Scholar
• Keren DF, Bocsi G, Billman BL, et al. Laboratory detection and initial diagnosis of monoclonal gammopathies. Arch Pathol Lab Med. 2022;146(5):575–590. doi:10.5858/arpa.2020-0794-CP.
   PubMed Web of Science ®Google Scholar
• Katzmann JA. Screening panels for monoclonal gammopathies: time to change. Clin Biochem Rev. 2009;30(3):105–111.
   PubMedGoogle Scholar
• Katzmann JA, Willrich MA, Kohlhagen MC, et al. Monitoring IgA multiple myeloma: immunoglobulin heavy/light chain assays. Clin Chem. 2015;61(2):360–367. doi:10.1373/clinchem.2014.231985.
   PubMed Web of Science ®Google Scholar
• Khurana U, Joshi D, Santoshi JA, et al. Oligosecretory multiple myeloma: a case report. Blood Res. 2016;51(1):63–65. doi:10.5045/br.2016.51.1.63.
   PubMedGoogle Scholar
• Udd KA, Spektor TM, Berenson JR. Monitoring multiple myeloma. Clin Adv Hematol Oncol. 2017;15(12):951–961.
   PubMedGoogle Scholar
• National minimum retesting intervals in pathology unique document number G147 document name national minimum retesting intervals in pathology; 2021. Accessed May18, 2023.
   Google Scholar
• Katerji R, Paczos T, Liu L. Test utilization of serum ­protein electrophoresis and immunofixation electrophoresis. Am J Clin Pathol. 2019;152(Supplement_1):S146–S147. doi:10.1093/ajcp/aqz130.011.
   PubMedGoogle Scholar
• Omar N, Madwani K, Moideen P, et al. Accurate quantification of monoclonal immunoglobulins migrating in the beta region on protein electrophoresis. Lab Med. 2022;53(2):138–144. doi:10.1093/labmed/lmab055.
   PubMed Web of Science ®Google Scholar
• Chae H, Han E, Yoo J, et al. Heavy/light chain assay as a biomarker for diagnosis and follow-up of multiple myeloma. Clin Chim Acta. 2018;479:7–13. doi:10.1016/j.cca.2018.01.010.
   PubMed Web of Science ®Google Scholar
• Rajkumar SV, Kyle RA, Therneau TM, et al. Serum free light chain ratio is an independent risk factor for progression in monoclonal gammopathy of undetermined significance. Blood. 2005;106(3):812–817. doi:10.1182/blood-2005-03-1038.
   PubMed Web of Science ®Google Scholar
• Kyle RA, Larson DR, Therneau TM, et al. Long-term follow-up of. Monoclonal gammopathy of undetermined significance. N Engl J Med. 2018;378(3):241–249. [Database] doi:10.1056/NEJMoa1709974.
   PubMed Web of Science ®Google Scholar
• Kyle RA, Durie BG, Rajkumar SV, et al. Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management. Leukemia. 2010;24(6):1121–1127. doi:10.1038/leu.2010.60.
   PubMed Web of Science ®Google Scholar
• Chahin M, Branham Z, Fox A, et al. Clinical considerations for immunoparesis in multiple myeloma. Cancers (Basel). 2022;14(9):2278. doi:10.3390/cancers14092278.
   PubMed Web of Science ®Google Scholar
• Landgren O, Hofmann JN, McShane CM, et al. Association of immune marker changes with progression of monoclonal gammopathy of undetermined significance to multiple myeloma. JAMA Oncol. 2019;5(9):1293–1301. doi:10.1001/jamaoncol.2019.1568.
   PubMed Web of Science ®Google Scholar
• Tate JR, Smith JD, Wijeratne N, et al. Proposed addendum to 2012 recommendations for standardised reporting of protein electrophoresis in Australia and New Zealand. Clin Biochem Rev. 2019;40(1):23–30.
   PubMedGoogle Scholar
• Booth RA, McCudden CR, Balion CM, et al. Candidate recommendations for protein electrophoresis reporting from the Canadian society of clinical chemists monoclonal gammopathy working group. Clin Biochem. 2018;51:10–20. doi:10.1016/j.clinbiochem.2017.10.013.
   PubMed Web of Science ®Google Scholar
• Wijeratne N, Tate JR, Wienholt L, et al. Report of the survey conducted by RCPAQAP on current practice for paraprotein and serum free light chain measurement and reporting: a need for harmonisation. Clin Biochem Rev. 2019;40(1):31–42.
   PubMedGoogle Scholar
• Sheldon J, Wheeler RD, Powles R. Electrophoretic patterns post daratumumab. Ann Clin Biochem. 2018;55(2):299–301. doi:10.1177/0004563217710489.
   PubMed Web of Science ®Google Scholar
• McCudden CR, Booth RA, Lin DCC, et al. Synoptic reporting for protein electrophoresis and immunofixation. Clin Biochem. 2018;51:21–28. doi:10.1016/j.clinbiochem.2017.09.020.
   PubMed Web of Science ®Google Scholar
• RCPA - Pathology Terminology and Information Stand­ardisation. Rcpa.edu.au. Published 2020. Accessed May 18, 2023.
   Google Scholar
• Wijeratne N, Tate JR, Toit SD, et al. Paraprotein sample exchange in Australia and New Zealand - 2018. Clin Biochem Rev. 2019;40(1):43–54.
   PubMedGoogle Scholar
• de Kat Angelino CM, Jacobs JFM. External quality ­assessment of M-protein diagnostics: a realistic impression of the accuracy and precision of M-protein quantification. Clin Chem Lab Med. 2021;59(6):1063–1068. doi:10.1515/cclm-2020-1810.
   PubMed Web of Science ®Google Scholar
• Ríos-Tamayo R, Puig N, Algarín M, et al. The current role of the heavy/light chain assay in the diagnosis, prognosis and monitoring of multiple myeloma: an evidence-based approach. Diagnostics (Basel). 2021;11(11):2020. doi:10.3390/diagnostics11112020.
   PubMedGoogle Scholar
• Moore LM, Cho S, Thoren KL. MALDI-TOF mass spectrometry distinguishes daratumumab from M-proteins. Clin Chim Acta. 2019;492:91–94. doi:10.1016/j.cca.2019.02.017.
   PubMed Web of Science ®Google Scholar
• Jawad MD, Go RS, Witzig TE, et al. Pseudo-monoclonal gammopathy: a report of four cases. Haematologica. 2017;102(11):e466–e469. doi:10.3324/haematol.2017.171694.
   PubMed Web of Science ®Google Scholar